![conference banner](/images/conference-banner.jpeg)
Abstract
(250 words): A diverse group of natural biological compounds bind to microtubules and suppress microtubule dynamics. Here we review the mechanism of microtubule assembly and dynamics as well as structural features that are important for nucleotide binding, GTP hydrolysis and stabilization of longitudinal and lateral protofilament contacts. Specific emphasis is placed upon the polar structure of the microtubule, the exposure of the nucleotide hydrolysis site at the + end and the conformational and configurational plasticity of the microtubule lattice. These features have important implications for the mechanism of dynamic instability and the disruptive action of antimitotic drugs. We then discuss the various classes of tubulin binding drugs emphasizing their site and mode of binding as well as the structural and energetic basis for their effects on microtubule assembly and dynamics. A common feature of tubulin-interacting compounds is a linkage to assembly, either the stabilization of a microtubul e lattice by compounds like taxol or epothilone A, or the preferential formation of alternate lattice contacts and polymers at microtubule ends by compounds like colchicine, vinca alkaloids and cryptophycin-52. Finally, we explore the likely possibility that these drugs also disrupt the regulation of microtubule dynamics. Future generations of these compounds may be selectively developed to directly target the proteins that regulate mitotic spindle dynamics.
Keywords: Tubulin-Interacting Antimitotic Drugs, GTP hydrolysis, Taxol, epothilone A, Colchicines, vinca alkaloids, cryptophycin-52, MAPs, Stathmin
Current Pharmaceutical Design
Title: Physiochemical Aspects of Tubulin-Interacting Antimitotic Drugs
Volume: 7 Issue: 13
Author(s): J. J. Correia and S. Lobert
Affiliation:
Keywords: Tubulin-Interacting Antimitotic Drugs, GTP hydrolysis, Taxol, epothilone A, Colchicines, vinca alkaloids, cryptophycin-52, MAPs, Stathmin
Abstract: (250 words): A diverse group of natural biological compounds bind to microtubules and suppress microtubule dynamics. Here we review the mechanism of microtubule assembly and dynamics as well as structural features that are important for nucleotide binding, GTP hydrolysis and stabilization of longitudinal and lateral protofilament contacts. Specific emphasis is placed upon the polar structure of the microtubule, the exposure of the nucleotide hydrolysis site at the + end and the conformational and configurational plasticity of the microtubule lattice. These features have important implications for the mechanism of dynamic instability and the disruptive action of antimitotic drugs. We then discuss the various classes of tubulin binding drugs emphasizing their site and mode of binding as well as the structural and energetic basis for their effects on microtubule assembly and dynamics. A common feature of tubulin-interacting compounds is a linkage to assembly, either the stabilization of a microtubul e lattice by compounds like taxol or epothilone A, or the preferential formation of alternate lattice contacts and polymers at microtubule ends by compounds like colchicine, vinca alkaloids and cryptophycin-52. Finally, we explore the likely possibility that these drugs also disrupt the regulation of microtubule dynamics. Future generations of these compounds may be selectively developed to directly target the proteins that regulate mitotic spindle dynamics.
Export Options
About this article
Cite this article as:
Correia J. J. and Lobert S., Physiochemical Aspects of Tubulin-Interacting Antimitotic Drugs, Current Pharmaceutical Design 2001; 7 (13) . https://dx.doi.org/10.2174/1381612013397438
DOI https://dx.doi.org/10.2174/1381612013397438 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Early Inflammatory Processes in the Skin
Current Molecular Medicine Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics Interaction of Tumor Suppressor p53 with DNA and Proteins
Current Pharmaceutical Biotechnology The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection
Current Pharmaceutical Design It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design Subcellular Imaging and Diagnosis of Cancer using Engineered Nanoparticles
Current Pharmaceutical Design The Application of Stable Isotope Assisted Metabolomics in Biomedicine
Current Biotechnology Nanostructure Thin Films of Titanium Dioxide Coated on Glass and Its Anti UV Effect for Living Organisms
Current Nanoscience Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders MicroRNA-16 Represses TGF-β1-induced Epithelial-to-Mesenchymal Transition in Human Lung Adenocarcinoma Cell Line
MicroRNA Functional Glyco-Affinity Precipitation/Capturing for Enhanced Affinity Proteomics
Current Proteomics Stem Cells for Ocular Tissue Engineering and Regeneration
Current Topics in Medicinal Chemistry Early Development of Therapeutic Biologics - Pharmacokinetics
Current Drug Metabolism Biology of Tenascin C and its Role in Physiology and Pathology
Current Medicinal Chemistry